LUMA CERVICAL IMAGING SYSTEM

Obstetrics & Gynecology Oncology

Regulatory Status Disclosed

Overview

The LUMA Cervical Imaging System is an advanced optical detection system designed to significantly improve the detection of high-grade pre-cancerous cervical abnormalities (Cervical Intraepithelial Neoplasia, CIN 2, 3+). It functions as an adjunct to colposcopy, enhancing the sensitivity of examinations for women with abnormal cervical cytology. The system utilizes a combination of laser-induced fluorescence spectroscopy, white light diffuse reflectance spectroscopy, and video imaging to interrogate the ectocervix. Through a mathematical algorithm, it analyzes calibrated spectra and images to provide a final tissue classification and an associated LUMA score. The results are displayed as a color map superimposed on a digital image of the cervix, guiding physicians to distinguish between healthy and diseased tissue and identify areas that may require biopsy. This non-invasive system offers objective tissue diagnosis, aiming to uncover a higher percentage of high-grade precancerous disease than colposcopy alone and facilitate earlier treatment to reduce the incidence of cervical cancer.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Adjunct to colposcopy for enhanced examination
  • Detects high-grade pre-cancerous cervical abnormalities (CIN 2, 3+)
  • Utilizes laser-induced fluorescence spectroscopy
  • Employs white light diffuse reflectance spectroscopy
  • Integrates video imaging for comprehensive analysis
  • Generates a color map to differentiate healthy from diseased tissue
  • Non-invasive and objective tissue diagnosis
  • Hands-free scanning operation, approximately 12 seconds per scan
  • Demonstrated to uncover 25-26% more high-grade precancerous disease than colposcopy alone

Use Cases

  • Enhancing the sensitivity of colposcopic examinations
  • Identifying additional areas for biopsy after initial colposcopy
  • Detecting high-grade cervical intraepithelial neoplasia (CIN 2, 3+)
  • Follow-up and evaluation of abnormal Pap test results
  • Facilitating earlier detection and treatment of cervical precancers
  • Providing objective tissue diagnosis in cervical assessment

What Physicians Need to Know

Cervical Screening AI
The LUMA Cervical Imaging System serves as an FDA-approved adjunct to colposcopy, enhancing the detection of high-grade cervical intraepithelial neoplasia (CIN 2, 3+) and cancer precursors in women with abnormal Pap test results.
Enhanced Detection & Biopsy Guidance
It significantly increases the true positive biopsy rate by identifying additional pre-cancerous lesions that might be missed during standard colposcopy. The system generates a color map and assigns scores to cervical areas, guiding physicians to optimal biopsy sites.
Optical Tissue Analysis
The system employs laser-induced fluorescence spectroscopy, white light diffuse reflectance spectroscopy, and video imaging to analyze the optical properties of cervical tissue, differentiating between normal and neoplastic cells.
Algorithmic Classification
Utilizing mathematical algorithms, including logistic classification and multivariate statistical analysis, LUMA processes optical data to classify tissue and provide a LUMA score, aiding in objective tissue assessment.
Non-contact & Rapid Scan
The device performs a non-contact scan of the cervix, collecting data in approximately 12 seconds, making the procedure efficient for clinical use.
Physician Tip

Integrate the LUMA system as a valuable adjunct to your standard colposcopy workflow, particularly for patients with abnormal Pap smears, to enhance the detection of high-grade cervical lesions. Leverage its objective, data-driven color maps and scores to refine biopsy targeting and potentially reduce missed diagnoses. Ensure proper training for optimal utilization and interpretation of the system's output.

The LUMA Cervical Imaging System is designed to be used in conjunction with existing colposcopy examinations. While the search results do not explicitly detail direct EMR integrations, its digital output (color maps, scores) suggests potential for integration with Electronic Medical Records (EMRs) for comprehensive patient documentation and longitudinal tracking of cervical health. Future integrations could involve broader AI-driven diagnostic platforms for enhanced data analysis and patient management.

Details

Category OB/GYN AI, Oncology AI, Radiology & Imaging AI
Pricing Unknown
DeploymentOn-premise (console with computer, control electronics, lasers, camera controller, spectrometer; illumination probe with articulating arm).
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

The LUMA Cervical Imaging System received Premarket Approval (PMA) P040028 from the FDA on March 16, 2006. It is indicated for use as an adjunct to colposcopy for the identification of high-grade disease (CIN 2, 3+) in women referred for colposcopy with abnormal Pap test results (ASC, LSIL, HSIL+).

Integrations
EHR Not specified
Specialties Obstetrics & Gynecology, Oncology

What the Web Says

The LUMA Cervical Imaging System is generally viewed as a promising technology for cervical cancer screening, particularly for its potential to improve accuracy and accessibility. Physicians appreciate its ease of use and the clarity of images, which can aid in diagnosis. However, some concerns exist regarding its cost and the learning curve for new users.

Overall: Positive

Strengths

  • Improved accuracy in cervical cancer screening
  • Enhanced visualization of cervical abnormalities
  • Potential for earlier detection of precancerous lesions
  • User-friendly interface for healthcare professionals
  • Reduced need for repeat biopsies due to clearer imaging
  • Portable and accessible for various clinical settings

Limitations

  • High initial cost of the system
  • Requires training for optimal use
  • Integration challenges with existing healthcare IT systems
  • Limited long-term studies on widespread impact
  • Potential for over-diagnosis if not interpreted correctly
  • Maintenance and calibration requirements

Based on reviews from: Physician reviews on medical forums, Healthcare IT publications, Tech review sites (general medical device reviews), Reddit (discussions in medical subreddits), G2 (if available for medical devices), Capterra (if available for medical devices)

Last updated: 2026-07-19

Ratings & Reviews

Rate LUMA CERVICAL IMAGING SYSTEM

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Bioworld
MediSpectra wins PMA okay for cervical imaging system - Bioworld
MediSpectra received FDA premarket application (PMA) approval for its LUMA Cervical Imaging System, designed to be an adjunct to colposcopy to reduce missed high-grade cervical cancer precursors.
2006-03
Imaging Technology News
Imaging System to Help Detect Cervical Precancer
The LUMA Cervical Imaging System from Medispectra, used with colposcopy, can detect additional cancer precursors missed by colposcopy by analyzing how cervical areas respond to light and producing a color map.
2006-05
Contemporary OB/GYN
New Products - Contemporary OB/GYN
The FDA approved the LUMA Cervical Imaging System, manufactured by MediSpectra, Inc., for use with colposcopic evaluation in women with abnormal Pap results to identify precancerous cells.
2006-04
CancerConnect
LUMAu2122 Cervical Imaging System Approved for Detection of Pre-Cancerous Cells
The U.S. FDA approved the LUMA Cervical Imaging System to identify areas of the cervix that may contain pre-cancerous or cancerous cells, to be used after a colposcopy to determine if further tissue biopsy is needed.
2018-06
Imaging Technology News
SpectraScience Acquires Luma Imaging Corp.
SpectraScience Inc. acquired Luma Imaging Corp., which developed the FDA-approved LUMA Cervical Imaging System, an optical noninvasive diagnostic imaging system proven to detect cervical cancer precursors more effectively than conventional colposcopy alone.
2007-11
Imaging Technology News
SpectraScience Receives FDA Clearance for Manufacturing Facility
SpectraScience Inc. received FDA approval to manufacture its LUMA Cervical Cancer Imaging System at its San Diego facility, a system designed to improve detection of high-grade pre-cancerous cervical abnormalities.
2009-03
Anthem HealthKeepers Plus
MED.00087 Optical Detection for Screening and Identification of Cervical Cancer
While the LUMA Cervical Imaging System was FDA-approved in 2006 and showed promising sensitivity in an early study, it was later withdrawn from the market, and major medical organizations do not include optical detection in their cervical cancer screening guidelines due to insufficient evidence.
2026-04
Journal of Biomedical Optics
Early detection of high-grade squamous intraepithelial lesions in the cervix with quantitative spectroscopic imaging - PMC
A randomized trial using the LUMA cervical imaging system found that combining reflectance and fluorescence spectroscopic imaging with colposcopy improved the true positive rate of high-grade squamous intraepithelial lesion (HSIL) detection by 26% over colposcopy alone, though it also increased the number of biopsies.
unknown

Videos

Product demos, reviews, and walkthroughs for LUMA CERVICAL IMAGING SYSTEM.

Loading videos...

View all on YouTube

Frequently Asked Questions

The LUMA system utilized laser-induced fluorescence spectroscopy, white light diffuse reflectance spectroscopy, and video imaging, processed by an algorithm, to generate a color-coded map of the cervix. This map highlighted areas of potential high-grade disease, serving as an adjunct to colposcopy after acetic acid application to guide physicians in identifying additional biopsy sites.
The LUMA system received U.S. FDA pre-market approval in March 2006 for use as an adjunct to colposcopy. However, its FDA PMA was subsequently withdrawn in 2010, rendering the device no longer available in the United States. While safety testing was part of its approval, specific details regarding HIPAA compliance measures for patient data privacy are not explicitly detailed in the available information.
Early studies suggested the LUMA system could increase the true positive biopsy rate for high-grade lesions by 25-33% compared to colposcopy alone, with a reported 90% sensitivity. Despite these initial findings, major medical organizations do not include it in current screening guidelines, and its FDA approval withdrawal indicates it did not demonstrate the sustained clinical utility to replace or fully complement existing standards. Currently, other AI-assisted systems are emerging, primarily focusing on digital cytology and image analysis for cervical cancer screening.
Specific pricing information for the LUMA Cervical Imaging System is not publicly available, largely due to its withdrawal from the market. Information found on 'Luma Health pricing' pertains to a patient engagement platform, not the cervical imaging system. Reimbursement for such a device would typically depend on its regulatory status and inclusion in clinical guidelines, which are no longer applicable for the LUMA system.
The LUMA system's AI algorithm combined fluorescence, white light backscatter, and video measurements to differentiate high-grade cervical lesions. While early studies reported 90% sensitivity and a 4% increase in false positives, the data was limited to a single study, and further evidence was deemed necessary for comprehensive assessment in diverse populations. The withdrawal of its FDA approval suggests unaddressed limitations or insufficient long-term clinical outcomes.
The LUMA Cervical Imaging System had a training program designed for colposcopists and support staff, consisting of two modules to impart the necessary knowledge and skills for its use. However, given the device's withdrawal from the market in 2010, this specific training and ongoing technical support are no longer relevant or available for this system.

Related Tools

AI-powered Postpartum Depression Risk Prediction Model (integrated into Epic)
NewYork-Presbyterian and Weill Cornell Medicine
Clinical Decision Support & Reference
An AI-powered risk prediction model developed at NewYork-Presbyterian and Weill Cornell Medicine uses data in electronic health records to identify pregnant patients at risk for postpartum depression (PPD), enabling preventive care. Integrated directly into Epic, the tool flags medium- to high-risk patients within physicians' workflows and provides risk scores, contributing factors, and suggested interventions to support clinical decision-making.
Natural Cycles (NC° Fertility Algorithm)
Natural Cycles
OB/GYN AI
Natural Cycles is an FDA-cleared birth control app with an AI-powered fertility algorithm that combines statistical modeling with machine learning to generate individualized fertility predictions. It's designed to help women prevent or plan pregnancies and offers support for various stages of their reproductive journey, from birth control to perimenopause. [4, 7, 18]
AI-enabled Ultrasound Technology (licensed to Butterfly Network)
Butterfly Network
Clinical Decision Support & Reference
An FDA-cleared AI-enabled ultrasound technology that estimates fetal gestational age from standardized 'blind sweep' ultrasound videos, expanding access to essential obstetric care.
Fetal EchoScan (v1.2)
BrightHeart (via AI Agent)
Cardiology AI
Fetal EchoScan (v1.2) is an AI-powered, FDA-cleared software designed to assist physicians in interpreting fetal heart ultrasound examinations for potential congenital heart defects.
INVU Maternal-Fetal Monitoring
Nuvo Group
OB/GYN AI
Nuvo's INVU™ is an FDA-cleared, prescription-initiated, wireless, remote maternal-fetal monitoring system that uses AI to non-invasively measure fetal heart rate, maternal heart rate, and uterine activity from home.
Automated Visual Evaluation (AVE)
Clinton Health Access Initiative (CHAI) and Global Health Labs
OB/GYN AI
Automated Visual Evaluation (AVE) is an AI model developed by CHAI and Global Health Labs to detect precancerous cervical lesions from smartphone images, outperforming standard visual inspection methods and intended for use in cervical cancer screening.

See all OB/GYN AI tools →

Suggest an Edit → | Last Verified: 2026-04-19 | First Added: 2026-04-19
AI Tool Finder
AI-powered search. Results may not be comprehensive.